Prescribers have unique real-world evidence needs, as clinical trial evidence is insufficient to guide treatment decisions for individuals in diverse subgroups, and clinical practice decisions require the synthesis of regulatory guidance, meta-analytic findings and the results of primary research studies.

Our research has shown that prescribers control the ultimate adoption of a new medicine, and our medical plans can be tailored to generate the right real-world evidence to optimise our clients’ success, reducing the time it takes for their new medicine to reach maximal adoption.